P53LAZARUS

"Tumour suppressor p53: structure, stability and novel anti-cancer drug development"

Coordinatore	MEDICAL RESEARCH COUNCIL    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	1˙459˙538 €
EC contributo	1˙459˙538 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2010-AdG_20100317
Funding Scheme	ERC-AG
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-08-01   -   2016-07-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	MEDICAL RESEARCH COUNCIL  Organization address address: NORTH STAR AVENUE POLARIS HOUSE city: SWINDON postcode: SN2 1FL contact info Titolo: Ms. Nome: Elizabeth Cognome: Cutler Email: send email Telefono: +44 122 340 2357	UK (SWINDON)	hostInstitution	1˙459˙538.00
2	MEDICAL RESEARCH COUNCIL  Organization address address: NORTH STAR AVENUE POLARIS HOUSE city: SWINDON postcode: SN2 1FL contact info Titolo: Prof. Nome: Alan Cognome: Fersht Email: send email Telefono: +44 791 952 8909	UK (SWINDON)	hostInstitution	1˙459˙538.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Elimination of the tumour suppression activities of p53 is common to all cancers. p53 is inactivated directly by mutation in ~50% of human cancers, and ~30-40% of these oncogenic mutants are just temperature sensitive, ts, being active at lower temperatures. Wild-type p53 spontaneously denatures, with a half-life of 10-20 minutes at body temperature, and ts mutants far faster. The melting temperature and half life of ts oncogenic mutants can be raised by small molecules. The mutant Y220C is particularly propitious for study and as a target for therapy as the mutation makes a druggable cavity. We discovered lead compounds for a novel class of anti-cancer drugs that could be used to treat 70-80,000 new cases of cancer per annum worldwide via reactivating Y220C. I present a programme to understand the basic principles of stabilising Y220C in particular and the thermodynamics and kinetics of ts mutant proteins in general. Such studies may aid the development of lead compounds for reactivating Y220C into prospective drugs and will act as a paradigm for development of the ¿holy grail¿ of a generic p53-reactivating drug. This is not a classical drug screening programme but a fundamental study on how to stabilise proteins whose poor stability causes disease, and which pulls together the twin interests of the applicant in fundamental protein folding and the structural biology of p53. I will investigate the biophysical and structural characteristics of how to stabilize proteins by small molecules using the leads thrown up by the drug-screening programme. Even if none of the leads make it to the clinic, they will be important substrates for the structure-activity studies on the mechanisms of protein stabilization, which will be of general importance.'